All In Biotech

Drug Trial Radar · NCT03187288

Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS

An Open-Label, Dose Escalation, Safety and Pharmacokinetic Study of CFI-400945 Fumarate Administered Orally to Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

13

Actual

Start

May 25, 2018

Primary completion

Jun 30, 2021

Study completion Jun 30, 2021

Sponsor

Lead sponsor
University Health Network, TorontoAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 14, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1 study of investigational drug CFI-400945 in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome. The purpose of this phase 1 study is to see how safe and tolerable the study drug is and to determine the best dose (maximum tolerated dose or recommended phase 2 dose) that can be given in this patient population.

Conditions

  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
  • Relapsed Cancer
  • Refractory Cancer

Interventions

  • CFI-400945 FumarateDrug

    CFI-400945 is an investigational drug that is being look at for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). CFI-400945 is an oral (taken by mouth) drug that blocks Polo-like kinase 4 (PLK4) activity. PLK4 is a protein that is important in regulating cell growth and division and cell death. Many tumors are shown to make too much PLK4. When there is too much PLK4 produced, it is believed to contribute to uncontrolled cancer cell growth and division. Therefore, by blocking this protein from working, it is believed to stop tumors from growing or shrink them.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluation of the frequency and severity of treatment-emergent adverse events in patientsTime frame: 5 years
  2. Highest tolerated dose of CFI-400945 fumarateTime frame: 5 years
  3. Recommended phase 2 dose of CFI-400945 fumarateTime frame: 5 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Juravinski Hospital and Cancer Centre

    Hamilton, Ontario, Canada

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.